STAG2 and melanoma: As supported, a previous study demonstrated that, although STAG2 inactivation did not affect the proliferation of BRAF-mutant melanoma cells, it markedly attenuated their response to RAF/MEK inhibitors by suppressing CCCTC-binding-factor (CTCF)-mediated expression of DUSP6 and subsequently reactivating ERK signaling [15].